Mao Fei, Liu Siying, Qiao Xiaona, Zheng Hangping, Xiong Qian, Wen Jie, Zhang Shuo, Zhang Zhaoyun, Ye Hongying, Shi Hongli, Lu Bin, Li Yiming
Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.
Department of Endocrinology and Metabolism, Jing'an Center Hospital of Shanghai, Shanghai 200040, P.R. China.
Exp Ther Med. 2017 Aug;14(2):1343-1350. doi: 10.3892/etm.2017.4689. Epub 2017 Jun 27.
SUDOSCAN is a non-invasive method of measuring peripheral small fiber and autonomic nerve activity by detection of abnormal sweat gland function through electrochemical skin conductance. It has been reported to be an effective screening tool in early detection of microvascular type 2 diabetes mellitus (T2DM) complications including diabetic neuropathy and nephropathy in recent studies. However, previous studies used estimated glomerular filtration rate (eGFR) as the golden standard, which has a 90% chance of being within 30% of the measured GFR at best. No relevant study has been performed in the Chinese population concerning SUDOSCAN in the screening of diabetic nephropathy (DN) in comparison with GFR. In this cross-sectional study, SUDOSCAN was performed in 176 Chinese patients with T2DM between September 2014 and September 2015. It was found that the SUDOSCAN test had a sensitivity of 57.8% and a specificity of 100% to detect chronic kidney disease at a cut-off SUDOSCAN-DN score of 59.5. The area under receiver operating characteristic curve for DN was 0.85 [95% confidence interval (CI), 0.76-0.93] compared with 0.84 for eGFR (MDRD, modification of diet in renal disease; 95% CI, 0.71-0.98) and 0.77 for eGFR (EPI, epidemiology collaboration; 95% CI, 0.68-0.87). Patients with DN score <59.5 had a significantly lower GFR level (P<0.001) and significantly older age (P<0.001), longer duration of T2DM (P<0.001) and higher risk of diabetic complications, including diabetic neuropathy (P<0.001) and peripheral vascular disease (P<0.05). These results suggested that SUDOSCAN may be useful for detecting patients at risk of impaired renal function as part of a screening program in the Chinese population with T2DM.
SUDOSCAN是一种通过电化学皮肤电导检测异常汗腺功能来测量外周小纤维和自主神经活动的非侵入性方法。最近的研究报道,它是早期检测2型糖尿病(T2DM)微血管并发症(包括糖尿病神经病变和肾病)的有效筛查工具。然而,以往研究将估算肾小球滤过率(eGFR)作为金标准,其最多只有90%的几率处于所测肾小球滤过率的30%范围内。在中国人群中,尚未有关于SUDOSCAN与肾小球滤过率相比在糖尿病肾病(DN)筛查中的相关研究。在这项横断面研究中,于2014年9月至2015年9月对176例中国T2DM患者进行了SUDOSCAN检测。结果发现,当SUDOSCAN-DN评分截断值为59.5时,SUDOSCAN检测慢性肾脏病的敏感性为57.8%,特异性为100%。DN的受试者操作特征曲线下面积为0.85 [95%置信区间(CI),0.76 - 0.93],相比之下,eGFR(MDRD,肾脏病饮食改良公式;95% CI,0.71 - 0.98)为0.84,eGFR(EPI,流行病学协作公式;95% CI,0.68 - 0.87)为0.77。DN评分<59.5的患者肾小球滤过率水平显著更低(P<0.001),年龄显著更大(P<0.001),T2DM病程更长(P<0.001),糖尿病并发症风险更高,包括糖尿病神经病变(P<0.001)和外周血管疾病(P<0.05)。这些结果表明,作为中国T2DM人群筛查项目的一部分,SUDOSCAN可能有助于检测肾功能受损风险患者。